Table 8 Cardiovascular and Cancer Events in ORIGIN LANTUS vs LANTUS STANDARD CARE STANDARD N=6264 N=6273 CARE n N Hazard Ratio (Events per 100 PY) (Events per 100 PY) (95% CI) Cardiovascular Co-primary endpoints CV death, non-fatal myocardial infarction, or 1041 1013 1.02 (0.94, nonfatal stroke 1.11) (2.9) (2.9) CV death, non-fatal myocardial infarction, 1792 1727 1.04 (0.97, stroke, hospitalisation for heart failure or 1.11) (5.5) (5.3) revascularisation procedure Components of co-primary endpoints CV death 1.00 (0.89, 580 576 1.13) Myocardial Infarction (fatal or non-fatal) 1.03 (0.88, 336 326 1.19) Stroke (fatal or non-fatal) 1.03 (0.89, 331 319 1.21) Revascularisations 1.06 (0.96, 908 860 1.16) Hospitalisation for heart failure 0.90 (0.77, 310 343 1.05) Cancer Cancer endpoints Any cancer event (new or recurrent) 559 561 0.99 (0.88, 1.11) (1.56) (1.56) New cancer events 524 535 0.96 (0.85, 1.09) (1.46) (1.49) Death due to Cancer 189 201 0.94 (0.77, 1.15) (0.51) (0.54) Severe hypoglycaemic attacks, especially if recurrent, may lead to neurological damage. Prolonged or severe hypoglycaemic episodes may be life-threatening.
Table 8 Cardiovascular and Cancer Events in ORIGIN LANTUS N=6264 STANDARD CARE N=6273 LANTUS vs STANDARD CARE n (Events per 100 PY) N (Events per 100 PY) Hazard Ratio (95% CI) Cardiovascular Co-primary endpoints CV death, non-fatal myocardial infarction, or nonfatal stroke 1041 (2.9) 1013 (2.9) 1.02 (0.94, 1.11) CV death, non-fatal myocardial infarction, stroke, hospitalisation for heart failure or revascularisation procedure 1792 (5.5) 1727 (5.3) 1.04 (0.97, 1.11) Components of co-primary endpoints CV death 580 576 1.00 (0.89, 1.13) Myocardial Infarction (fatal or non-fatal) 336 326 1.03 (0.88, 1.19) Stroke (fatal or non-fatal) 331 319 1.03 (0.89, 1.21) Revascularisations 908 860 1.06 (0.96, 1.16) Hospitalisation for heart failure 310 343 0.90 (0.77, 1.05) Cancer Cancer endpoints Any cancer event (new or recurrent) 559 (1.56) 561 (1.56) 0.99 (0.88, 1.11) New cancer events 524 (1.46) 535 (1.49) 0.96 (0.85, 1.09) Death due to Cancer 189 (0.51) 201 (0.54) 0.94 (0.77, 1.15) Severe hypoglycaemic attacks, especially if recurrent, may lead to neurological damage. Prolonged or severe hypoglycaemic episodes may be life-threatening.
auspar-insulin-glargine-rbe-170106-pi.docx